Literature DB >> 6200644

[Bleomycin-induced pulmonary infiltrations in the treatment of testicular cancer].

C Clemm, R Hartenstein, B Mayr, W Wilmanns.   

Abstract

Under Cisplatinum/Vinblastine/Bleomycin treatment six of 82 patients with nonseminomatous testicular cancer developed a Bleomycin-induced pulmonary toxicity. After a total Bleomycin dose of 300-360 mg all six patients showed multiple nodular densities near the pleura in the basal lung areas on the computed tomographic scanning (CT). Disseminated interstitial infiltrates, mostly in the lower lung fields were spontaneously observed by means of chest X-rays in only one case. In two other cases only minimal changes were found retrospectively. In five cases the diffusion capacity did not decrease significantly. Diffusion capacity, vital capacity and oxygen fell significantly in only one case. The latter was also the only patient showing clinical symptoms. The lung changes were completely reversible in four patients 4-6 months after cessation of Bleomycin. In two patients there were reversible residual changes after a timespan of 20 and 24 months. Two patients received no further antineoplastic treatment, two were under maintenance therapy, two under further induction chemotherapy because of the assumption of lung metastases. None of the six patients show any evidence at present of testis tumor (observation period 17-34 months). It can be difficult to distinguish between Bleomycin-induced lung damage and tumor metastases by radiological means. We were able to differentiate by observing the clinical course of the six patients. In case of doubt a histological examination is strongly recommended.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6200644     DOI: 10.1007/bf01738705

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  21 in total

1.  Staging of early nonseminomatous germ-cell testicular cancer.

Authors:  E E Fraley; P H Lange; R D Williams; S A Ortlip
Journal:  Cancer       Date:  1980-04-15       Impact factor: 6.860

2.  Pulmonary fibrosis in experimental acute respiratory disease.

Authors:  K M Reiser; J A Last
Journal:  Am Rev Respir Dis       Date:  1981-01

3.  The pulmonary toxicity of antineoplastic agents.

Authors:  S J Ginsberg; R L Comis
Journal:  Semin Oncol       Date:  1982-03       Impact factor: 4.929

Review 4.  [Fibrosing alveolitis (interstitial pneumonia)].

Authors:  R Rubin
Journal:  Prax Klin Pneumol       Date:  1982-04

5.  Fatal pulmonary reaction from low doses of bleomycin. An idiosyncratic tissue response.

Authors:  J R Iacovino; J Leitner; A K Abbas; J J Lokich; G L Snider
Journal:  JAMA       Date:  1976-03-22       Impact factor: 56.272

6.  Phase II evaluation of bleomycin. A Southwest oncology Group study.

Authors:  C D Haas; C A Coltman; J A Gottlieb; A Haut; J K Luce; R W Talley; B Samal; H E Wilson; B Hoogstraten
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

7.  Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture.

Authors:  L H Einhorn
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

8.  Bleomycin therapy and anaesthesia. The possible hazards of oxygen administration to patients after treatment with bleomycin.

Authors:  S C Allen; G S Riddell; E G Butchart
Journal:  Anaesthesia       Date:  1981-01       Impact factor: 6.955

9.  Pulmonary complications of chemotherapy regimens containing bleomycin.

Authors:  J P Balikian; M S Jochelson; K A Bauer; A T Skarkin; M B Garnick; G P Canellos; E H Smith
Journal:  AJR Am J Roentgenol       Date:  1982-09       Impact factor: 3.959

10.  Reversibility of severe bleomycin-induced pneumonitis.

Authors:  W G Brown; F M Hasan; R A Barbee
Journal:  JAMA       Date:  1978-05-12       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.